COMPANY PROFILE

Amplifica

Explore full profile

A biopharmaceutical company focused on developing novel treatments to address androgenic alopecia (hair loss)

San Diego, United StatesBiotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amplifica

Amplifica Holdings Group, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for hair regrowth. The company has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair, which forms the core of its technology. Amplifica is currently initiating clinical trials to evaluate the safety and efficacy of its treatments, while also working to obtain all necessary regulatory approvals. The company's approach is grounded in molecular biology, specifically the study of naturally occurring hairy nevi, which has been extensively researched and uniquely understood by Amplifica.

Amplifica serves clients experiencing hair loss, targeting a market that includes individuals seeking effective hair regrowth solutions. The business model is based on developing and commercializing its proprietary technology through clinical trials and subsequent market approval. Revenue generation will primarily come from the sale of its therapeutic products once they receive regulatory clearance.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Headquarters: San Diego, United States
Open positions: None listed
Dealroom signal: 25.1/100
Industry: Health, Wellness Beauty
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Aug 2026	$26M	$104M	Eli Lilly · Associated Partners, LP · Scopia Capital Management · Tasso Partners	↗
SERIES A✓Equity / VC	Oct 2022	$12M	$47M	SternAegis Ventures	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Amplifica website traffic

Latest recorded traffic for Amplifica is 250 monthly website visits, down 86.1% over the last three months.

Latest monthly visits250 3-month web change-86.1%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HEHenlezDeveloped first-in-class enzyme treatment to treat dermatological conditions	Kongens Lyngby, Denmark	Operational	7	$1.1M	$4.4M
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
ASATAI Life SciencesA biotechnology company pioneering mental health innovation	Berlin, Germany	Acquired
ONOneSkinA longevity company on a mission to transform the way we think about skin and aging	San Francisco, United States	Operational
OBObsEvaInnovating Women’s Reproductive Health Therapeutics	Geneva, Switzerland	Operational
SESeriTechInnovative Health and Skin Care	Barcelona, Spain	Operational
ALAliformOur company, Aliform is developing a medical device to help plastic surgeons treat cellulite easier	Aachen, Germany	Operational
DIDerm-Biome Pharmaceuticals, IncWe are a preclinical biotech company with safe and highly effective topical treatments for inflammatory skin diseases and skin cancer #acne #eczema	Vancouver, Canada	Operational